BioSpace News Archive

$5M cash infusion received in warrant exercises and upfront money from a licensing deal “2020 was a pivotal year for Can-Fite as we demonstrated a robust clinical proof of concept for both Piclidenoson and Namodenoson,” stated Can-Fite CEO Dr. Pnina Fishman

Results From ILLUMINATE-301 To Be Discussed Webinar To Be Held on Wednesday, March 31, 2021 at 12:00 p.m. ET.

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced it has completed enrollment and dosing of all participants in the Company’s Phase 1 trial of its novel, oxygen enhancing therapeutic, trans sodium crocetinate (“TSC”)

BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced financial results for the full year 2020 and provided an update on its business.

In a first of its kind approval, the FDA granted Emergency Use Authorization to Tiger Tech’s COVID screening device.

Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, announced the company has been selected to the Fortune 2021 list of Best Workplaces in Health Care & Biopharma™.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that initial patient enrollment in the second dose cohort in the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial in fit and unfit patients with relapsed or refractory Acute Myeloid Leukemia (r/r AML) has been completed

Episode Six, the global provider of modern payment processing and banking infrastructure, announced its expansion into the U.S. healthtech market - a sector ripe for innovation with healthcare expenditure hitting nearly $3.7 trillion in 2018, per CMS projections.

Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Alain Van Loo to serve as its Chief Operating Officer.

Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that its Chief Executive Officer, Mr. James Nathanielsz